{"id":"ABBV","quote":{"symbol":"ABBV","name":"AbbVie Inc.","price":148.32,"changesPercentage":0.4946,"change":0.73,"dayLow":146.9,"dayHigh":148.8,"yearHigh":168.11,"yearLow":130.96,"marketCap":261792213627,"priceAvg50":142.9204,"priceAvg200":150.5199,"exchange":"NYSE","volume":2469192,"avgVolume":5552273,"open":148.12,"previousClose":147.59,"eps":4.85,"pe":30.58,"earningsAnnouncement":"2023-10-26T00:00:00.000+0000","sharesOutstanding":1765049984,"timestamp":1693425788},"priceChange":{"symbol":"ABBV","1D":0.4946,"5D":0.88423344,"1M":-0.8423586,"3M":7.50942,"6M":-3.62573,"ytd":-8.6587,"1Y":10.3079,"3Y":54.87105,"5Y":54.53219,"10Y":248.25076,"max":322.32346},"profile":{"symbol":"ABBV","price":148.32,"beta":0.54728,"volAvg":5552273,"mktCap":261792213627,"lastDiv":5.92,"range":"130.96-168.11","changes":0.73,"companyName":"AbbVie Inc.","currency":"USD","cik":"0001551152","isin":"US00287Y1091","cusip":"00287Y109","exchange":"New York Stock Exchange","exchangeShortName":"NYSE","industry":"Drug Manufacturers—General","website":"https://www.abbvie.com","description":"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.","ceo":"Mr. Richard A. Gonzalez","sector":"Healthcare","country":"US","fullTimeEmployees":"50000","phone":"847 932 7900","address":"1 North Waukegan Road","city":"North Chicago","state":"IL","zip":"60064-6400","dcfDiff":16.3514,"dcf":162.631,"image":"https://financialmodelingprep.com/image-stock/ABBV.png","ipoDate":"2013-01-02","defaultImage":false,"isEtf":false,"isActivelyTrading":true,"isAdr":false,"isFund":false}}